Appointments at Takeda, Aquapharm and Cannabis Science – People on the move

By Nick Taylor

- Last updated on GMT

Related tags: Board of directors, Vice president

in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Takeda, Aquapharm and Cannabis Science.

Takeda Pharmaceutical​ has appointed Shankar Suryanarayanan​ to head its operations in India, according to The Financial Express​. Reports state that Takeda is looking to enter the Indian market, possibly through acquisition, and the former Roche and Novartis employee is part of this.

Jorgen Thorball​ has been appointed as chairman of the board of directors at PergamumAB​. Thorball has senior executive experience at companies including Pharmacia, Aventis and Novozymes. He also founded BioGaia Healthcare Sweden in 1997.

Aquapharm Biodiscovery ​has appointed Lloyd Payne​ as its research director. Payne joins Aquapharm from F2G and has also worked at Millennium Pharmaceuticals, Cambridge Discovery Chemistry and NCE Discovery.

Chemical and plastics company Borealis​ has appointed Gerd Löbbert​ as executive vice president (VP) for base chemicals. Before joining Borealis Löbbert worked at BASF for 23 years.

William Keller​ has been appointed to the board of directors at Alexion Pharmaceuticals​. Keller has more than 30 years experience in the pharma industry at companies including Roche and Keller Pharma Consultancy, a China-based business he founded.

Cannabis Science​ has appointed Ben Johnson​, Allan Shackleford​ and William Courtney​ as members of its recently formed scientific advisory board.

Howard McEldowney ​has been appointed as an independent director on the board of directors at American Diversified Holdings Corporation​, a company with a focus on stem cells. McEldowney has worked at Chemical Bank and co-founded Harris, Bretail and McEldowney.

Venture capital firm Canaan Partners​ has appointed Tim Shannon​ to support its healthcare portfolio companies and identify new investment targets. Shannon was CEO of CuraGen, which was bought by Celldex Therapeutics in October, and has also worked at Bayer.

Related topics: Markets & Regulations

Related news

Show more

Follow us


View more